|For Immediate Release
Vantage Oncology Announces Joint Venture with Valley Radiothreapy Associates Medical Group to Form Center for Radiation Therapy of Beverly Hills - Cancer Center to offer Patients Convenient Access to the Most Advanced Radiation Therapy Treatments
BEVERLY HILLS, CA (January 18, 2012) – In its continued efforts to provide innovative radiation therapy treatment to cancer patients in the Los Angeles County, Vantage Oncology, a Manhattan Beach, Calif.-based developer and operator of state-of-the-art radiation oncology centers, has announced a joint venture with Valley Radiotherapy Associates Medical Group, Inc. (VRA) to form the Center for Radiation Therapy of Beverly Hills. The facility is located at 9229 Wilshire Blvd. in Beverly Hills, CA, 90210. The center has been operating under Vantage Oncology since November 28th, 2011.
“The joint venture between Valley Radiotherapy Associates and Vantage Oncology will provide local patients access to state-of-the-art diagnostic and radiation therapy services,” said Michael T. Fiore, CEO of Vantage Oncology. “In combination with the extensive expertise of the physicians and clinical staff, I am confident that our team of experts will become a vital and highly regarded cancer treatment resource for patients in Beverly Hills and surrounding communities.”
The center’s radiation oncology services will be spearheaded by a highly trained and experienced clinical team of board certified radiation oncologists. May-Lin Tao, MD, MSPH, and Henry Yampolsky, MD, will serve as Medical Directors of the center bringing their vast clinical expertise, research and educator backgrounds to bear. Christopher Rose, MD, a former president of the American Society for Radiation Oncology (ASTRO) and Leslie Botnick, MD, Chief Medical Officer and Co-Founder of Vantage Oncology, and CEO of VRA are also part of the clinical team.
The diversity and multi-cultural backgrounds of their clinical team and staff offers the community several spoken languages. "Our mission is to deliver personalized care to each and every patient of every community,” said Dr. May-Lin Tao, a breast cancer clinical expert and researcher who has written much on the quality of life of cancer patients and survivors and outcomes of modern breast cancer treatment. With our state-of-the-art facilities and a team of highly-trained physicians, radiation therapists, oncology nurses, and other support staff, I am confident that our center will provide the most comprehensive treatment and compassionate care in the Beverly Hills area."
Patients will have access to exceptional physicians and today’s most advanced and clinically proven radiotherapy technologies. Our goal is to provide not only highly precise and accurate treatment but also efficient and comfortable care. The center boasts innovative technologies including GE 4-D CT Simulation for imaging and planning, Varian RapidArc™ Intensity Modulated and Image-Guided Radiation Therapy (IMRT/IGRT), Stereotactic Ablative Body Radiotherapy (SABR), Stereotactic Radiosurgery (SRS) for the brain, Calypso® 4D localization for real time tracking of the prostate and Varian Real time Position Management (RPMTM) respiratory gating.
“With our multi-disciplinary approach to treating malignancies today, our technology and our evidence-based treatment protocols will result in superior outcomes for our patients. New technologies, such as Varian RapidArc™, offer more efficient delivery of radiation treatment and Calypso (‘GPS for the Body” ®), enables us to deliver higher, more effective doses of radiation to the prostate with fewer complications and side effects,” said Dr. Rose, Chief Technology Officer of VRA and Vantage Oncology.
Dr. Yampolsky, who has a strong background in computer sciences and biochemistry, is pleased with the new joint venture and seeks to build upon the center’s history of innovation. “Our center will strive to be the leader in cancer care in this market by proactively assessing newer technologies that enhance the comfort, convenience, and treatment quality for our patients.”
As part of the joint venture agreement, Vantage Oncology will provide operations management and funding for facility and technology upgrades to support the center’s efforts to provide academic quality cancer care in a patient-friendly environment.
“We are looking forward to this new joint venture with Vantage Oncology because it provides us with an outstanding platform for maximizing the quality of oncologic care in Beverly Hills and surrounding communities,” said Dr. Botnick.
About Valley Radiotherapy Associates Medical Group, Inc.
Valley Radiotherapy Associates Medical Group, Inc. (VRA) of Manhattan Beach, California, was founded by Leslie E. Botnick, M.D., and Christopher M. Rose, M.D., in June, 1983 to deliver radiation oncology services. Today, VRA Medical Group has 34 board-certified radiation oncologists and provides advanced radiation therapy services to communities at 17 centers in Los Angeles, Orange, Riverside, Imperial Valley and San Bernardino Counties in California. VRA has distinguished itself during the past 25 years as one of the premier radiation oncology groups in the nation with a proven record of excellence in clinical treatment, superiority in service delivery and technical acumen to develop new cancer treatment programs. For more information about VRA, visit www.valley-radiotherapy.com.
About Vantage Oncology
Founded in October 2002, Manhattan Beach, California-based Vantage Oncology, LLC, develops and operates radiation oncology centers of excellence through acquisitions and joint ventures. The company’s founding principals was to address the growing need among cancer patients, hospitals and physicians for easily accessible and advanced radiation treatment therapies. Vantage Oncology currently operates 46 treatment facilities in 13 states. Vantage Oncology is led by a seasoned management team including Chief Executive Officer and Co-Founder Michael Fiore, Chief Medical Officer and Co-Founder, Leslie Botnick, M.D., Chief Financial Officer Marshal Salomon and Chief Development Officer Mark Ahern. For more information about Vantage Oncology, visit www.vantageoncology.com.
# # #